SB Global Advisers’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

SB Global Advisers’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$14.3M	Hold	12,100,078	–	–	1.66%	7
2022 Q3	$24.7M	Hold	12,100,078	–	–	1.82%	7
2022 Q2	$18.6M	Hold	12,100,078	–	–	0.88%	7
2022 Q1	$61.1M	Hold	12,100,078	–	–	1.92%	7
2021 Q4	$75M	Buy	+12,100,078	New	+$108M	1.49%	7

Other funds holding PEAR

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SB Global Advisers's PEAR Position: Q4 2022 in Review

SB Global Advisers held its Pear Therapeutics, Inc. Class A Common Stock (PEAR) position steady in Q4 2022 at 12,100,078 shares worth $14.3M. The position accounts for 1.66% of the portfolio, ranked #7.

SB Global Advisers first reported a position in PEAR in Q4 2021 and has held it in 5 quarters since. The position peaked at $75M in Q4 2021. 64 funds tracked by Wall St. Rank hold PEAR as of Q4 2022.

SB Global Advisers held 12,100,078 shares of Pear Therapeutics, Inc. Class A Common Stock worth $14.3M as of Q4 2022.
SB Global Advisers left its Pear Therapeutics, Inc. Class A Common Stock share count unchanged in Q4 2022.
Pear Therapeutics, Inc. Class A Common Stock made up 1.66% of SB Global Advisers's portfolio in Q4 2022, its #7 holding.
SB Global Advisers first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and has held it in 5 quarters since.
SB Global Advisers's Pear Therapeutics, Inc. Class A Common Stock position peaked at $75M in Q4 2021.
64 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2022.

Based on SB Global Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.